BioCardia (NSDQ:BCDA) said today it filed for a second FDA investigational device exemption to launch a trial of its CardiAMP cell therapy of chronic myocardial ischemia and refractory angina as it seeks a second indication.
The San Carlos, Calif.-based company’s CardiAMP therapy uses autologous cells to treat chronic myocardial ischemia, and is designed to stimulate the body’s natural healing response.
Read the whole story on our Sister Site, Drug Delivery Business